Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10238-021-00751-7 http://scihub22266oqcxt.onion/10.1007/s10238-021-00751-7 34424451!8381864!34424451     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Exp+Med 2022 ; 22 (3): 327-346 Nephropedia Template TP {{tp|p=34424451|t=2022. COVID-19-associated opportunistic infections: a snapshot on the current reports |pdf=|usr=}}{{34424451}} gab.com Text COVID-19-associated opportunistic infections: a snapshot on the current reports JO: Clin Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=34424451 #FOAvip Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a complicated challenge, especially among patients with severe disease. In recent studies, immunosuppressive therapy has shown promising results for control of the cytokine storm syndrome (CSS) in severe cases of COVID-19. However, it is well documented that immunosuppressive agents (e.g., corticosteroids and cytokine blockers) increase the risk of opportunistic infections. On the other hand, several opportunistic infections were reported in COVID-19 patients, including Aspergillus spp., Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci (carinii), mucormycosis, Cytomegalovirus (CMV), Herpes simplex virus (HSV), Strongyloides stercoralis, Mycobacterium tuberculosis, and Toxoplasma gondii. This review is a snapshot about the main opportunistic infections that reported among COVID-19 patients. As such, we summarized information about the main immunosuppressive agents that were used in recent clinical trials for COVID-19 patients and the risk of opportunistic infections following these treatments. We also discussed about the main challenges regarding diagnosis and treatment of COVID-19-associated opportunistic infections (CAOIs). Twit Text FOAVip COVID-19-associated opportunistic infections: a snapshot on the current reports ????Clin Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=34424451 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34424451 #FOAvip English Wikipedia <ref>{{Cite pmid|34424451}}</ref> COVID-19-associated opportunistic infections: a snapshot on the current reports #MMPMID34424451 Abdoli A; Falahi S; Kenarkoohi A Clin Exp Med 2022[Aug]; 22 (3): 327-346 PMID34424451show ga Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a complicated challenge, especially among patients with severe disease. In recent studies, immunosuppressive therapy has shown promising results for control of the cytokine storm syndrome (CSS) in severe cases of COVID-19. However, it is well documented that immunosuppressive agents (e.g., corticosteroids and cytokine blockers) increase the risk of opportunistic infections. On the other hand, several opportunistic infections were reported in COVID-19 patients, including Aspergillus spp., Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci (carinii), mucormycosis, Cytomegalovirus (CMV), Herpes simplex virus (HSV), Strongyloides stercoralis, Mycobacterium tuberculosis, and Toxoplasma gondii. This review is a snapshot about the main opportunistic infections that reported among COVID-19 patients. As such, we summarized information about the main immunosuppressive agents that were used in recent clinical trials for COVID-19 patients and the risk of opportunistic infections following these treatments. We also discussed about the main challenges regarding diagnosis and treatment of COVID-19-associated opportunistic infections (CAOIs). |*COVID-19 Drug Treatment[MESH] |*COVID-19/complications[MESH] |*Candidiasis/complications[MESH] |*Cytomegalovirus Infections/drug therapy[MESH] |*Opportunistic Infections/complications/drug therapy/epidemiology[MESH] |*Pneumonia, Pneumocystis/etiology[MESH] |Humans[MESH]COVID-19-associated opportunistic infections: a snapshot on the curren(epmc).pdf DeepDyve Pubget Overpricing